A study by researchers at Indiana University, Methodist Research Institute that is published in The International Journal of Oncology reveals that a non-toxic, botanical orally administered formula controls aggressive human prostate tumors in mice.

The peer-reviewed pre-clinical in vivo study demonstrated that the prostate formula substantially suppresses tumor growth in aggressive, hormone-refractory (androgen-independent) human prostate cancer cells without any toxic side effects, even when administered at high doses. The formula is a combination of botanical extracts, phytonutrients, botanically enhanced medicinal mushrooms and antioxidants.

Inventor of the formula, Dr. Isaac Eliaz declared:

“This study is a milestone in the research of this formula, demonstrating its safety and effectiveness in treating human prostate cancer in an animal model. These positive results offer a significant contribution to prostate cancer research and add to the growing body of published data substantiating the role of natural compounds in the treatment of prostate cancer.”

This is the third study from a major university which has demonstrated the formula’s ability to suppress tumor growth and metastasis.

Leading researcher Dr. Daniel Silva remarks:

“Multiple studies have demonstrated that this prostate formula is a possible treatment for hormone-refractory prostate cancer.”

The study results showed that in comparison to controls, the formula managed to suppress tumor growth by 27% and substantially reduced the size of the tumor. It also blocked several genes, i.e. IGF2, NRNF2 and PLAU/uPA, which encourage cancer proliferation and metastasis. It furthermore increased CDKN1A expression, a gene that fights prostate cancer by blocking cellular mechanisms that promote cancer.

All of these characteristics prove that the formula has multiple anti-cancer mechanisms and genetic targets and confirm earlier published in vitro data that showed that the formula lowers the expression of PLAU/uPA genes in aggressive, hormone-independent prostate cancer cells.

The formula was previously studied at Columbia University and the Cancer Research Laboratory, Methodist Research Institute, at Indiana University Health, where the findings were also confirmed.

Written by Petra Rattue